Fig 2.

Median total out-of-pocket costs for a course of oral anticancer therapies for Part D beneficiaries by drug before (2010) and after (2020) the doughnut hole closes, with the assumption of a median duration treatment course. Analysis is based on the July 15, 2014, quarterly release of the Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Files from the Centers for Medicare & Medicaid Services. Input price is from the formulary files and represents the average reimbursed amount across each plan for the product listed for 1 month of therapy at the mean recommended dose. Median duration of use was obtained from data provided in Howard et al.¹⁵ For products not included in Howard et al, we used the drug product label to identify median duration of therapy (Data Supplement).